[go: up one dir, main page]

ZA200810850B - High affinity human and humanized anti-+-5²1 integrin function blocking antibodies with reduced immunogenicity - Google Patents

High affinity human and humanized anti-+-5²1 integrin function blocking antibodies with reduced immunogenicity

Info

Publication number
ZA200810850B
ZA200810850B ZA200810850A ZA200810850A ZA200810850B ZA 200810850 B ZA200810850 B ZA 200810850B ZA 200810850 A ZA200810850 A ZA 200810850A ZA 200810850 A ZA200810850 A ZA 200810850A ZA 200810850 B ZA200810850 B ZA 200810850B
Authority
ZA
South Africa
Prior art keywords
high affinity
humanized anti
reduced immunogenicity
blocking antibodies
affinity human
Prior art date
Application number
ZA200810850A
Other languages
English (en)
Inventor
Andreas Menrad
Joerg Willuda
Klaus Bosslet
Dieter Zopft
Heike Petrul
Stefan Steidl
Josef Prassler
Corinne Petit-Frere
Original Assignee
Bayer Schering Pharma Ag
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Morphosys Ag filed Critical Bayer Schering Pharma Ag
Publication of ZA200810850B publication Critical patent/ZA200810850B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
ZA200810850A 2006-05-24 2008-12-23 High affinity human and humanized anti-+-5²1 integrin function blocking antibodies with reduced immunogenicity ZA200810850B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06010779 2006-05-24

Publications (1)

Publication Number Publication Date
ZA200810850B true ZA200810850B (en) 2010-05-26

Family

ID=38659612

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200810850A ZA200810850B (en) 2006-05-24 2008-12-23 High affinity human and humanized anti-+-5²1 integrin function blocking antibodies with reduced immunogenicity

Country Status (23)

Country Link
US (1) US20090081207A1 (es)
EP (1) EP2032605A2 (es)
JP (1) JP2009537158A (es)
KR (1) KR20090027218A (es)
CN (1) CN101495515A (es)
AR (1) AR061107A1 (es)
AU (1) AU2007253586A1 (es)
BR (1) BRPI0711796A2 (es)
CA (1) CA2652886A1 (es)
CL (1) CL2007001488A1 (es)
CR (1) CR10456A (es)
DO (2) DOP2007000101A (es)
EA (1) EA200802348A1 (es)
EC (1) ECSP088909A (es)
MA (1) MA30425B1 (es)
MX (1) MX2008014910A (es)
NO (1) NO20085362L (es)
PE (1) PE20080100A1 (es)
TN (1) TNSN08469A1 (es)
TW (1) TW200817433A (es)
UY (1) UY30362A1 (es)
WO (1) WO2007134876A2 (es)
ZA (1) ZA200810850B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2481756T3 (en) 2005-10-31 2017-10-09 Oncomed Pharm Inc Compositions and Methods for Diagnosing and Treating Cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP1989231B1 (en) 2006-03-21 2015-05-20 Genentech, Inc. Combinatorial therapy involving alpha5beta1 antagonists
PE20091029A1 (es) 2007-09-26 2009-08-19 Genentech Inc Anticuerpos anti-alfa 5 beta 1
CA2714071A1 (en) * 2008-02-05 2009-08-13 Bristol-Myers Squibb Company Alpha 5 - beta 1 antibodies and their uses
CN105079805A (zh) 2008-09-26 2015-11-25 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
EP2356154A4 (en) * 2008-11-06 2012-12-19 Alexion Pharma Inc DEVELOPMENT OF REDUCED IMMUNOGENICITY ANTIBODIES AND METHODS OF MANUFACTURING THEREOF
AU2009331528A1 (en) * 2008-12-23 2011-08-11 Astrazeneca Ab Targeted binding agents directed to alpha5beta1 and uses thereof
NZ594343A (en) 2009-03-25 2013-10-25 Genentech Inc Novel anti-alpha5beta1 antibodies and uses thereof
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
NZ602700A (en) 2010-04-01 2014-10-31 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
ES2540114T3 (es) * 2010-07-09 2015-07-08 Affibody Ab Polipéptidos
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
EP2545905A1 (en) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
TWI586378B (zh) 2012-03-13 2017-06-11 瑞斯比維特有限公司 新穎醫藥調配物
WO2014066328A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
MX2015008534A (es) * 2012-12-26 2017-07-04 Oncosynergy Inc COMPOSICIONES DE ANTICUERPO ANTI-INTEGRINA ß1 Y METODOS DE USO DE LAS MISMAS.
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CA2987884C (en) * 2015-06-28 2023-01-03 Allgenesis Biotherapeutics Inc. Fusion peptides comprising disintegrin binding to integrin .alpha.v.beta.x or .alpha.5.beta.1 and their use in treating an angiogenic disease
US12383634B2 (en) * 2019-07-24 2025-08-12 Korea Basic Science Institute Single domain antibody targeting αVβ3 integrin
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013495A (en) * 1994-10-21 2000-01-11 The Scripps Research Institute Methods of use for integrin B1C cell growth inhibitor
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US7276589B2 (en) * 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7285268B2 (en) * 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
NZ540562A (en) * 2002-11-26 2008-04-30 Pdl Biopharma Inc Therapeutic chimeric and humanized antibodies directed against alpha5beta1 integrin, methods for purification of these antibodies, and their use in treating conditions comprising undesirable tissue angiogenesis
WO2005092073A2 (en) * 2004-03-24 2005-10-06 Pdl Biopharma, Inc. Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
EP1989231B1 (en) * 2006-03-21 2015-05-20 Genentech, Inc. Combinatorial therapy involving alpha5beta1 antagonists

Also Published As

Publication number Publication date
TW200817433A (en) 2008-04-16
DOP20070101A (es) 2007-12-30
KR20090027218A (ko) 2009-03-16
PE20080100A1 (es) 2008-04-18
JP2009537158A (ja) 2009-10-29
WO2007134876A8 (en) 2009-07-02
DOP2007000101A (es) 2007-12-31
ECSP088909A (es) 2008-12-30
MA30425B1 (fr) 2009-05-04
CA2652886A1 (en) 2007-11-29
CN101495515A (zh) 2009-07-29
WO2007134876A3 (en) 2008-03-27
AR061107A1 (es) 2008-08-06
AU2007253586A1 (en) 2007-11-29
CL2007001488A1 (es) 2008-01-04
US20090081207A1 (en) 2009-03-26
BRPI0711796A2 (pt) 2011-12-06
EA200802348A1 (ru) 2009-08-28
WO2007134876A2 (en) 2007-11-29
EP2032605A2 (en) 2009-03-11
MX2008014910A (es) 2009-01-23
UY30362A1 (es) 2008-01-02
TNSN08469A1 (en) 2010-04-14
NO20085362L (no) 2009-02-23
CR10456A (es) 2009-02-26

Similar Documents

Publication Publication Date Title
ZA200810850B (en) High affinity human and humanized anti-+-5²1 integrin function blocking antibodies with reduced immunogenicity
IL272883A (en) Monoclonal antibodies and their uses
HRP20181969T1 (hr) Humanizirana protutijela protiv čimbenika d i njihova upotreba
IL200610A0 (en) Human monoclonal anti-ip-10 antibodies and uses thereof
IL240245A (en) 5t4 antibodies and their uses
ZA200804148B (en) Anti-alpha2 integrin antibodies and their uses
IL194266A0 (en) Anti-igf-ir antibodies and uses thereof
IL195101A0 (en) Antibodies and immunoconjugates and uses therefor
ZA201002209B (en) Antibodies and immunoconjugates and uses therefor
IL193922A0 (en) Anti-tat226 antibodies and immunoconjugates
ZA200809776B (en) Antibodies and immunoconjugates and uses therefor
IL187710A0 (en) Anti-trkb monoclonal antibodies and uses thereof
SI2061814T1 (sl) Protitelesa in imunokonjugati in njihove uporabe
IL203429A0 (en) Immunogenic polypeptides and monoclonal antibodies
EP2077325A4 (en) MONOCLONAL ANTIBODY AND ITS USE